Joanna Przybyl
PhD
Dr. Przybyl is an Assistant Professor in the Department of Surgery, Â鶹AV and a Principal Investigator in the Cancer Research Program of the Research Institute of the Â鶹AV Health Centre (RI-MUHC).Â
Dr. Przybyl is also an Associate Member of the Department of Pathology, Â鶹AV, and an Associate Member of the Division of Experimental Medicine in the Department of Medicine, Â鶹AV.
Dr. Przybyl pursues a research program focused on the clinical applications of liquid biopsy, metabolic reprogramming and multi-omic profiling of sarcoma.Â
Dr. Joanna Przybyl received a joint Ph.D. degree in biomedical sciences from KU Leuven, Belgium and Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. Her doctoral studies focused on identifying new prognostic and predictive markers for soft tissue sarcoma. She then joined the laboratory of Dr. Matt van de Rijn in the Department of Pathology at Stanford University, where she completed her postdoctoral training in computational biology. During her postdoctoral studies, Dr. Przybyl demonstrated potential clinical utility of ctDNA monitoring in patients with leiomyosarcoma and leiomyoma, discovered activation and prognostic role of hexosamine biosynthesis pathway in leiomyosarcoma, and identified macrophage infiltration in undifferentiated uterine sarcomas.Â
Dr. Przybyl's research group employs multi-omic high-throughput experimental methods and bioinformatic tools to discover new therapeutic targets and markers for diagnosis and classification of soft tissue sarcomas. The goal of her research is to develop clinically applicable assays and investigate new therapeutic approaches that will improve care for patients with soft tissue tumours.